Anifrolumab (Saphnelo) for systemic lupus erythematosus

Med Lett Drugs Ther. 2021 Sep 20;63(1633):146-147.
No abstract available

Keywords: Benlysta; Cellcept; Cytoxan; Imuran; Metoject; Plaquenil; Procytox; Rheumatrex; Rituxan; Saphnelo; adverse effects; anifrolumab; azathioprine; belimumab; corticosteroids; cyclophosphamide; dosage; efficacy; hydroxychloroquine; lactation; lupus; methotrexate; mycophenolate mofetil; pregnancy; rituximab; safety.

MeSH terms

  • Adrenal Cortex Hormones / administration & dosage
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Double-Blind Method
  • Drug Approval
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Lupus Erythematosus, Systemic / drug therapy*
  • Randomized Controlled Trials as Topic
  • Severity of Illness Index
  • United States
  • United States Food and Drug Administration

Substances

  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • anifrolumab